460 related articles for article (PubMed ID: 21668856)
21. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
22. [Vaccination with allergens in children].
Demoly P; Dhivert-Donnadieu H; Bousquet J
Allerg Immunol (Paris); 2000 Dec; 32(10):397-401. PubMed ID: 11209473
[TBL] [Abstract][Full Text] [Related]
23. Rush immunotherapy with sublingual administration of grass allergen extract.
Feliziani V; Marfisi RM; Parmiani S
Allergol Immunopathol (Madr); 1993; 21(5):173-8. PubMed ID: 8160561
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma.
Nasser S; Vestenbaek U; Beriot-Mathiot A; Poulsen PB
Allergy; 2008 Dec; 63(12):1624-9. PubMed ID: 19032235
[TBL] [Abstract][Full Text] [Related]
25. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
[TBL] [Abstract][Full Text] [Related]
26. Sustained effects of grass pollen AIT.
Durham SR;
Allergy; 2011 Jul; 66 Suppl 95():50-2. PubMed ID: 21668855
[TBL] [Abstract][Full Text] [Related]
27. Tolerability and efficacy of house dust mite AIT.
Mosbech H
Allergy; 2011 Jul; 66 Suppl 95():55-6. PubMed ID: 21668857
[TBL] [Abstract][Full Text] [Related]
28. Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX®) in a real-life setting for three consecutive seasons - the GRAAL trial.
Wessel F; Chartier A; Meunier JP; Magnan A
Clin Drug Investig; 2012 Jul; 32(7):451-63. PubMed ID: 22594491
[TBL] [Abstract][Full Text] [Related]
29. Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention.
Halken S
Pediatr Allergy Immunol; 2004 Jun; 15 Suppl 16():4-5, 9-32. PubMed ID: 15125698
[TBL] [Abstract][Full Text] [Related]
30. Oralair(®): a causal treatment for grass pollen-induced allergic rhinoconjunctivitis.
Köberlein J; Mösges R
Immunotherapy; 2013 Jan; 5(1):13-21. PubMed ID: 23256794
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis.
Worm M
Eur Ann Allergy Clin Immunol; 2006 Dec; 38(10):355-60. PubMed ID: 17274520
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
[TBL] [Abstract][Full Text] [Related]
33. The relevance of patient-reported outcomes in a grass pollen immunotherapy trial in children and adolescents with rhinoconjunctivitis.
Röder E; Berger MY; Hop WC; de Groot H; van Wijk RG
Pediatr Allergy Immunol; 2013 Feb; 24(1):39-48. PubMed ID: 22882319
[TBL] [Abstract][Full Text] [Related]
34. [Sublingual specific immunotherapy for rhinoconjunctivitis caused by grass pollens].
Sabbah A; Lesellin J; Hassoun S; Sicard H; André C
Allerg Immunol (Paris); 1993 Jun; 25(6):241-7. PubMed ID: 8357473
[TBL] [Abstract][Full Text] [Related]
35. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial.
Caffarelli C; Sensi LG; Marcucci F; Cavagni G
Allergy; 2000 Dec; 55(12):1142-7. PubMed ID: 11117271
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe.
Canonica GW; Poulsen PB; Vestenbaek U
Respir Med; 2007 Sep; 101(9):1885-94. PubMed ID: 17611095
[TBL] [Abstract][Full Text] [Related]
37. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
38. Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen.
Wüthrich B; Bucher Ch; Jörg W; Bircher A; Eng P; Schneider Y; Schnyder F; Eigenmann P; Senti G
J Investig Allergol Clin Immunol; 2003; 13(3):145-8. PubMed ID: 14635462
[TBL] [Abstract][Full Text] [Related]
39. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.
Didier A; Malling HJ; Worm M; Horak F; Jäger S; Montagut A; André C; de Beaumont O; Melac M
J Allergy Clin Immunol; 2007 Dec; 120(6):1338-45. PubMed ID: 17935764
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective.
Bachert C; Vestenbaek U; Christensen J; Griffiths UK; Poulsen PB
Clin Exp Allergy; 2007 May; 37(5):772-9. PubMed ID: 17456225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]